MedTrace Logo

The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

NCT01905202 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-08-04

No results posted yet for this study

Summary

Secretrol administered over a 6 month period to patients with Barrett's Esophagus will be safe and well tolerated. Further, pH control will be evaluated in the distal esophageal mucosa and just below the squamocolumnar junction.

Conditions

  • Barrett's Esophagus

Interventions

DRUG

Secretrol

Sponsors & Collaborators

  • Effexus Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Prateek Sharma, M.D. · Kansas City, Missouri VAMC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01905202 on ClinicalTrials.gov